Last updated: August 6, 2026

CLINIMIX 5/35 Sulfite-Free is a hospital parenteral nutrition product containing 5% amino acids and 35% dextrose in a plastic container. Its commercial outlook is driven by hospital nutrition demand, sterile manufacturing capacity, supply reliability, reimbursement, and Baxter’s broader intravenous-solutions portfolio rather than by patent exclusivity.

The product has limited standalone financial transparency. Baxter does not publicly report revenue, gross margin, unit volume, or market share for this specific CLINIMIX presentation. The product’s economic value is best assessed as part of the U.S. parenteral nutrition and large-volume intravenous products market.

What is CLINIMIX 5/35 Sulfite-Free used for?

CLINIMIX 5/35 Sulfite-Free is used for parenteral nutrition when oral or enteral feeding is not possible, inadequate, or contraindicated. The formulation supplies amino acids as a nitrogen source and dextrose as calories. Electrolytes, vitamins, minerals, and lipid emulsions may be added or administered separately according to patient requirements.

The product is intended for intravenous administration after appropriate preparation and clinical assessment. The high dextrose concentration generally makes central venous administration relevant because of osmolarity constraints. The FDA-approved labeling describes the product as a source of calories and protein for patients requiring parenteral nutrition.[1]

Attribute	Product characteristic
Brand	CLINIMIX
Presentation	5% amino acids in 35% dextrose
Sulfite status	Sulfite-free
Dosage form	Intravenous parenteral nutrition solution
Container	Plastic container
Primary customer	Hospitals, health systems, infusion providers
Manufacturer	Baxter Healthcare Corporation
Therapeutic market	Clinical nutrition and intravenous therapy
Key substitutes	Other premixed amino-acid/dextrose solutions, compounded PN, individualized compounded bags

The sulfite-free designation is commercially relevant for patients with sulfite sensitivity and for institutional formularies that standardize on preservative-free or sulfite-free nutrition products.

How large is the market for premixed parenteral nutrition?

The addressable market is a specialized segment of hospital pharmaceuticals. Demand comes from intensive-care units, oncology services, surgery, gastroenterology, neonatology, long-term acute-care hospitals, and patients with intestinal failure.

Market growth is linked to:

Aging populations and higher hospital utilization.
Greater survival among critically ill patients.
Increased use of nutrition support in oncology and gastrointestinal disease.
Hospital efforts to reduce manual compounding.
Pharmacy labor shortages and the need for ready-to-use products.
Supply-chain disruptions affecting sterile injectables.
Clinical preference for enteral nutrition when feasible, which limits long-term growth in parenteral nutrition.

Premixed products such as CLINIMIX compete with individualized pharmacy-compounded nutrition. Premixed bags generally offer lower preparation labor and shorter operational turnaround. Compounded formulations provide greater flexibility for electrolytes, micronutrients, fluid volume, and patient-specific macronutrient requirements.

The market therefore has two opposing forces. Hospital labor and sterile-compounding constraints support premixed products. Clinical customization and efforts to use enteral feeding where appropriate limit substitution toward standardized premixed bags.

What drives demand for CLINIMIX 5/35?

Hospital pharmacy economics

Premixed CLINIMIX products can reduce pharmacy preparation time, clean-room workload, and compounding complexity. Their value is often measured against the fully loaded cost of compounding rather than against the acquisition price alone.

Hospitals consider:

Product acquisition cost.
Pharmacy labor.
Clean-room utilization.
Beyond-use dating.
Waste from unused compounded bags.
Inventory carrying costs.
Risk of compounding errors.
Availability of alternative concentrations.
Contract pricing under group purchasing agreements.

A shortage of pharmacists or sterile-compounding technicians can increase demand for premixed PN even when the product carries a higher invoice price than raw ingredients.

Clinical demand

Demand is concentrated in patients who cannot receive adequate enteral nutrition. Common use cases include severe gastrointestinal dysfunction, bowel obstruction, short-bowel syndrome, prolonged ileus, severe malabsorption, and selected critically ill patients.

The American Society for Parenteral and Enteral Nutrition recommends individualized nutrition strategies based on disease state, gastrointestinal function, clinical condition, and route feasibility.[2] Those clinical requirements create continuing demand for both premixed and compounded PN.

Supply reliability

Sterile injectable products are exposed to manufacturing interruptions, raw-material shortages, quality events, and limited production redundancy. A manufacturer that can maintain supply during disruptions can gain hospital formulary preference and contract volume.

Baxter’s role as a major supplier of intravenous solutions and parenteral nutrition products makes manufacturing continuity a central commercial variable. The 2024 disruption at Baxter’s North Cove, North Carolina facility affected the U.S. supply of intravenous fluids and triggered federal and industry responses.[3] The event demonstrated that a single facility interruption can affect hospitals, distributors, competitors, and downstream compounded products.

What is the financial trajectory of CLINIMIX 5/35?

No public filing isolates CLINIMIX 5/35 Sulfite-Free revenue. Baxter reports financial performance at broader business-unit and product-category levels. The product’s financial trajectory must therefore be inferred from portfolio conditions.

Financial factor	Likely effect on CLINIMIX 5/35
Hospital admissions	Supports volume
Premixed PN adoption	Supports volume and utilization
Generic sterile-injectable competition	Pressures price
Group purchasing contracts	Limits pricing power
IV-fluid shortages	Can increase demand but also restrict supply
Raw-material inflation	Pressures gross margin
Plastic and energy costs	Pressures manufacturing cost
Pharmacy labor shortages	Supports premixed products
Enteral nutrition preference	Limits market expansion
Product recalls or plant disruptions	Can reduce shipments and create remediation costs

The most probable trajectory is mature, stable demand with periodic volume and pricing volatility. This is not a high-growth specialty pharmaceutical product. Its commercial profile resembles a recurring hospital-supply product with defensible manufacturing scale and operational importance.

Revenue can rise during shortage periods because of temporary demand, emergency purchasing, and higher realized prices. Those gains may not persist after supply normalizes. Conversely, a manufacturing interruption can produce a sharp decline in shipments even when underlying demand remains strong.

Baxter’s public reporting should be used to evaluate broader trends in its Pharmaceuticals, Medical Products and Therapies, and intravenous-therapy activities. Those disclosures provide portfolio context but do not establish the revenue or profitability of this individual CLINIMIX presentation.[4]

What patents protect CLINIMIX 5/35 Sulfite-Free?

CLINIMIX 5/35 is unlikely to have meaningful patent-driven exclusivity comparable to a novel small-molecule drug or biologic. The active components are established nutrients, including amino acids and dextrose. The commercial barriers are primarily manufacturing, regulatory, quality, distribution, and contracting barriers.

Potential intellectual-property categories include:

Container and flexible-bag design.
Multi-chamber or dual-chamber packaging.
Mixing and activation systems.
Sterile manufacturing processes.
Formulation stability.
Compatibility of amino acids, dextrose, electrolytes, and additives.
Packaging materials and oxygen-barrier systems.
Methods for reducing degradation or particulate formation.

These rights may protect particular manufacturing systems or packaging configurations without creating broad exclusivity over amino-acid/dextrose parenteral nutrition.

Orange Book and FDA exclusivity

The product does not have the commercial profile of a product protected by long-term new chemical entity exclusivity. Any FDA exclusivity associated with an original approval would not be expected to remain a material barrier for a mature formulation containing long-established nutritional ingredients.

The FDA Orange Book is the relevant source for approved drug applications, therapeutic equivalence evaluations, and listed patents.[5] For this product, the practical competitive question is whether an applicant can obtain approval and reliably manufacture an equivalent sterile product, not whether a long-lived composition-of-matter patent blocks entry.

When does CLINIMIX 5/35 lose exclusivity?

CLINIMIX 5/35 is already a mature product with no apparent remaining exclusivity period that would materially determine market access. Its market position depends on supply and contracting rather than on an imminent patent cliff.

Exclusivity category	Relevance to CLINIMIX 5/35
New chemical entity exclusivity	Not commercially relevant
Orphan-drug exclusivity	Not applicable to the formulation
Pediatric exclusivity	No material current impact identified
Composition-of-matter patent	Not expected to be the main barrier
Formulation patent	Could affect a specific presentation, if enforceable
Container patent	Could affect packaging design, not the nutrient category
Regulatory exclusivity	Mature-product relevance is limited
Trade-secret manufacturing know-how	Potentially important

Are there Paragraph IV challenges or generic launch risks?

A conventional generic or abbreviated approval pathway could create competition if the competing product meets the applicable pharmaceutical equivalence, sterility, stability, container, labeling, and manufacturing requirements.

The primary risks are:

A competitor launches an equivalent amino-acid/dextrose product.
A hospital system substitutes a compounded formulation.
A rival obtains a supply contract through lower pricing.
A shortage accelerates formulary conversion to another supplier.
A distributor reduces reliance on a single manufacturer.
A competitor offers more useful concentrations, bag sizes, or electrolyte options.

Paragraph IV litigation is less likely to be the central entry mechanism than in conventional tablet or capsule markets. If no blocking patent is listed for the relevant application and presentation, an ANDA applicant would not need to defeat a major patent estate before competing. The practical barrier is FDA-compliant sterile manufacturing at commercial scale.

How strong is the CLINIMIX patent estate?

The patent estate is likely weak as a source of broad market exclusivity but stronger as an operational moat when combined with manufacturing capabilities.

Patent-estate dimension	Assessment
Active-ingredient protection	Weak
Broad formulation protection	Limited
Container and delivery systems	Potentially moderate
Manufacturing know-how	Potentially strong
Sterility and quality systems	Strong practical barrier
Regulatory history	Valuable but not exclusive
Distribution scale	Strong commercial advantage
Hospital contracts	Important but reversible
Switching costs	Moderate

The distinction matters for valuation. A competitor may be able to avoid a packaging patent while still facing high costs to build a qualified sterile facility, validate the process, establish stability data, secure raw materials, pass inspections, and obtain hospital approval.

What manufacturing barriers affect competition?

Manufacturing is the principal barrier to entry.

A new supplier must manage:

Sterile compounding and aseptic processing.
High-volume intravenous bag filling.
Container-closure integrity.
Particulate and endotoxin control.
Amino-acid and dextrose stability.
Compatibility with plastic materials.
Transport and storage conditions.
Batch release testing.
Pharmacopoeial compliance.
FDA inspection readiness.
Reliable procurement of amino acids, dextrose, packaging film, and ports.

Parenteral nutrition products also require tight control of formulation consistency. Manufacturing failures can produce recalls, hospital shortages, and regulatory action. The cost of qualification and the consequences of failure favor established suppliers.

Which companies compete with CLINIMIX?

Competition includes branded pharmaceutical suppliers, generic sterile-injectable manufacturers, compounding pharmacies, and hospital-owned outsourcing facilities.

Relevant competitive categories include:

Competitor category	Competitive advantage
Baxter CLINIMIX	Established hospital relationships and portfolio breadth
Fresenius Kabi	Parenteral nutrition and injectable-product capabilities
B. Braun	Intravenous therapy and nutrition infrastructure
Hospital pharmacies	Patient-specific customization
Outsourcing facilities	Scalable compounded PN
Regional compounders	Local responsiveness and special formulations
Other generic manufacturers	Price competition and alternative supply

The competitive landscape varies by hospital contract, geographic distribution, shortage conditions, and the availability of specific concentrations.

What is the biosimilar risk for CLINIMIX 5/35?

There is no biosimilar risk. CLINIMIX is a nonbiologic nutritional drug product. Competitive risk comes from generic sterile products, compounded parenteral nutrition, and alternative premixed formulations.

The relevant regulatory and commercial questions are pharmaceutical equivalence, sterility, stability, container performance, and supply capacity rather than biologic similarity or interchangeability.

What litigation and settlement risks affect CLINIMIX?

No major product-specific patent settlement or Paragraph IV settlement is established by the public materials cited here. Litigation risk is more likely to arise from:

Manufacturing defects.
Product recalls.
Contamination or particulate claims.
Labeling and administration errors.
Contract disputes.
Supply failures.
Competition over container or delivery-system patents.
Hospital or distributor claims arising from shortages.

The 2024 Baxter IV-fluid supply disruption also created operational and commercial exposure across hospitals and suppliers, although supply disruption should not be treated as evidence of a CLINIMIX-specific legal outcome.[3]

What is the FDA regulatory status of CLINIMIX 5/35?

CLINIMIX 5/35 Sulfite-Free is an FDA-regulated prescription intravenous nutrition product. The label governs indications, dosing, administration, warnings, storage, preparation, and compatibility.[1]

Regulatory risk centers on:

Sterility assurance.
Container integrity.
Stability and expiration dating.
Labeling accuracy.
Manufacturing changes.
Product complaints.
Shortage management.
Post-market quality surveillance.

Because the ingredients are familiar, clinical novelty is limited. FDA scrutiny remains high because the product is sterile and administered intravenously.

What generic launch scenarios exist?

Scenario 1: Stable incumbent supply

Baxter maintains supply and hospitals continue using established contracts. Competition remains price-sensitive but gradual. Revenue is broadly stable, with changes tied to volumes, hospital purchasing, and input costs.

Scenario 2: Competitor price entry

A generic supplier offers a lower-priced equivalent. Baxter may face contract repricing, volume migration, or narrower margins. Hospitals with standardized formularies may switch quickly if equivalence and supply reliability are established.

Scenario 3: Shortage-driven substitution

A Baxter disruption causes hospitals to use another premixed product or compounded PN. Some conversions reverse after supply returns; others become permanent if hospitals validate an alternative and renegotiate contracts.

Scenario 4: Compounding expansion

Hospitals or outsourcing facilities increase individualized PN production. This can reduce demand for fixed premixed concentrations, particularly for patients requiring customized electrolytes or fluid volumes.

Scenario 5: Portfolio-based defense

Baxter uses its broader IV-therapy portfolio, distribution network, and hospital contracts to retain share even if the individual product faces price pressure.

How does CLINIMIX compare with individualized compounded PN?

Issue	CLINIMIX 5/35	Individualized compounded PN
Customization	Limited	High
Pharmacy labor	Low	High
Preparation speed	Fast	Slower
Sterility responsibility	Manufacturer	Compounder
Waste risk	Higher if unused	Can be tailored
Electrolyte adjustment	Limited by product	Patient-specific
Supply risk	Manufacturer-dependent	Facility- and ingredient-dependent
Cost predictability	Generally higher	Variable
Use in complex patients	May require additions	Strong fit
Hospital standardization	Easy	More complex

The product is strongest where hospitals value speed, standardized protocols, and reduced compounding workload. It is weaker where patient-specific formulations dominate.

Key Takeaways

CLINIMIX 5/35 Sulfite-Free is a mature premixed parenteral nutrition product supplied by Baxter.
No public source isolates the product’s revenue, margin, volume, or market share.
Its financial trajectory is likely stable but exposed to hospital demand, contract pricing, manufacturing interruptions, and sterile-product input costs.
Patent exclusivity is not the primary commercial defense.
Manufacturing scale, sterility systems, regulatory history, distribution, and hospital contracts are more important than composition patents.
Generic and compounded-PN competition can pressure price and volume without requiring a major Paragraph IV patent battle.
There is no biosimilar risk.
Baxter’s 2024 IV-fluid manufacturing disruption demonstrates the supply concentration risk affecting this category.
The strongest commercial scenario is reliable supply combined with hospital contract retention.
The main downside scenario is a supply interruption that accelerates permanent conversion to a competing premixed or compounded product.

FAQs

Is CLINIMIX 5/35 Sulfite-Free a generic drug?

It is a branded premixed parenteral nutrition product. Competition can come from generic or alternative amino-acid/dextrose products, but the relevant barriers are sterile manufacturing and FDA compliance.

Does CLINIMIX 5/35 have patent protection?

Any protection is more likely to involve packaging, delivery systems, stability, or manufacturing methods than the amino-acid and dextrose ingredients themselves.

Can hospitals replace CLINIMIX 5/35 with compounded parenteral nutrition?

Yes. Hospitals can use individualized compounded PN when they have the appropriate sterile-compounding capability, quality systems, ingredients, and clinical protocols.

What is the main investment risk for CLINIMIX?

The main risks are supply disruption, contract repricing, manufacturing remediation, sterile-product competition, and substitution by compounded or competing premixed nutrition products.

Does CLINIMIX 5/35 have biosimilar competition?

No. Biosimilar rules apply to biologic products, while CLINIMIX is a nonbiologic parenteral nutrition formulation.

References

U.S. Food and Drug Administration. (n.d.). CLINIMIX-5% amino acids and 35% dextrose injection, solution label. DailyMed.
American Society for Parenteral and Enteral Nutrition. (2022). ASPEN guidelines and clinical resources for parenteral nutrition. ASPEN.
U.S. Food and Drug Administration. (2024). FDA updates on IV fluid supply following Baxter manufacturing disruption. FDA.
Baxter International Inc. (2024). Annual report for the fiscal year ended December 31, 2023.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	020734-018	Sep 29, 1997		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

Pharmacology for CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER